LONDON BROKER RATINGS: Deutsche Bank likes Vodafone and raises Avacta
19th Jun 2024 09:43
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday: Read More
Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to chief executive officer from head of Research & Development. Coughlin has been an Avacta board member since March 2022 and head of R&D since this past February. She replaces Alastair Smith, who steps down on Tuesday after 19 years as CEO. Coughlin was CEO of Cytolmmune Therapeutics, which develops cell therapy solutions from a facility in Puerto Rico. She also has worked at Pfizer Inc and Novartis AG. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000. Read More
Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand." Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy. Read More
Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group. Read More
(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended. Read More
Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile. Read More